Drug
Pelacarsen (TQJ230)
Pelacarsen (TQJ230) is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph phase_3
2
67%
Ph not_applicable
1
33%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
2(66.7%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Terminated(1)
Detailed Status
Recruiting2
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 32 (66.7%)
N/A1 (33.3%)
Trials by Status
withdrawn133%
recruiting267%
Recent Activity
2 active trials
Showing 3 of 3
recruitingphase_3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263
recruitingphase_3
Pelacarsen Roll-over Extension Program
NCT06875973
withdrawnnot_applicable
Influence of Pelacarsen on Patients After Myocardial Infarction With High Lp(a) Values (PEMILA)
NCT04993664
Clinical Trials (3)
Showing 3 of 3 trials
NCT07517263Phase 3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT06875973Phase 3
Pelacarsen Roll-over Extension Program
NCT04993664Not Applicable
Influence of Pelacarsen on Patients After Myocardial Infarction With High Lp(a) Values (PEMILA)
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3